Abstract
BackgroundAchieving remission is the ideal goal in treating rheumatoid arthritis (RA). In a randomised phase 3 trial, high remission and low disease activity (LDA) rates were achieved with baricitinib (BARI)....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have